-
Kenya's economy faces climate change risks: World Bank
-
German growth beats forecast but energy shock looms
-
Air France-KLM trims 2026 outlook over Middle East war impact
-
Oil surges 7% to top $126 on Trump blockade warning
-
Volkswagen warns of more cost cuts as profits plunge
-
Rolls-Royce confident on profits despite Mideast war disruption
-
French economy records zero growth in first quarter
-
Carmaker Stellantis swings back into profit as sales climb
-
Trump warns Iran blockade could last months, sending oil prices soaring
-
Denmark's Soren Torpegaard Lund to 'stay true' at Eurovision
-
Mamdani calls on King Charles to return Koh-i-Noor diamond
-
Key points from the first global talks on phasing out fossil fuels
-
Cuban boy's sporting dreams on hold as surgery backlog grows
-
Bali drowning in trash after landfill closed
-
ECB set to hold rates despite Iran war energy shock
-
Samsung Electronics posts record quarterly profit on AI boom
-
Meta chief Zuckerberg doubles down on AI spending
-
Google-parent Alphabet soars as Meta stumbles over AI costs
-
Brazil lowers benchmark rate to 14.5% in second consecutive cut
-
Google-parent Alphabet soars as rivals stumble over AI costs
-
Anti-Bezos campaign urges Met Gala boycott in New York
-
African oil producers defend need to drill at fossil fuel exit talks
-
'Gritty' Philadelphia pitches itself as low-cost US World Cup choice
-
'I literally was a fool': Musk grilled in OpenAI trial
-
OpenAI facing 'waves' of US lawsuits over Canada mass shooting
-
Ticket price hikes not affecting summer air travel demand: IATA
-
Uber adds hotel booking in push to become 'everything app'
-
Oil spikes while stocks slip ahead of US Fed rate decision
-
Canada holds key rate steady, says will act if war inflation persists
-
Trump warns Iran better 'get smart soon' and accept nuclear deal
-
US Fed chief's plans in focus as central bank set to hold rates steady
-
German inflation jumps in April as energy costs surge
-
UBS first-quarter profits jump 80% on investment banking
-
Finnish lift maker Kone acquires German rival TKE, creating giant
-
Diving robot explores mystery of France's deepest shipwreck
-
Much-needed rains revive Iraq's fabled Mesopotamian Marshes
-
Adidas reports higher profits but warns of 'volatile' climate
-
TotalEnergies first-quarter profits surge amid Middle East war
-
King Charles to stress UK-US cultural, trade ties in New York
-
Mercedes-Benz profit slides amid cutthroat Chinese market
-
Cheaper, cleaner electric trucks overhaul China's logistics
-
Europe climate report signals rising extremes
-
An experimental cafe run by AI opens in Stockholm
-
Jerome Powell: Fed chair who stood up to Trump set to finish tenure on top
-
Pentagon makes deal to expand use of Google AI: reports
-
France unveils plan to ditch all fossil fuels by 2050
-
Crude back above $110 on Strait stalemate as US stocks retreat
-
Germany holds breath as stranded whale 'Timmy' sets off in barge
-
King Charles urges Western unity in speech to US Congress
-
US Supreme Court hears Cisco bid to halt Falun Gong suit
Ozempic slimming craze sweeps Kosovo despite side effects
Kosovo influencer Tringa Kadriu sees the slimming drug Ozempic as a chance to shed excess pounds -- and she is not the only one in her Balkan nation, where more than half the population is overweight.
"I want to lose 15-16 kilos (33-35 pounds) in two months," Kadriu, 29, told AFP, "and then I'll continue with fitness".
Ozempic, approved in the United States to treat diabetes in 2017, has found an international market for people trying to lose weight.
Despite its cost, the drug has soared in popularity in Kosovo, a country of 1.7 million.
While Kosovo authorities have not sanctioned the drug's use for weight loss, they have noted their limited means to confront use of a drug widely available in the country.
Merita Emini-Sadiku, who heads the Kosovo university hospital's endocrinology clinic, said the cost of the drug had soared.
"The monthly dose used to be 75-80 euros ($85-91), while now it is 130-140 euros ($147-159), probably due to high demand," she said.
But she warned that "Ozempic has side effects that people are not aware of".
Ozempic use can potentially cause issues including thyroid cancer, pancreatitis, gastroparesis and bowel obstruction, according to the latest studies.
- 'Constant demand' -
Meant to treat Type 2 diabetes -- of which the WHO says Kosovo has lower than average levels -- the drug regulates blood sugar levels but also helps suppress hunger, leading to a lower calorie intake.
As a result, its potentially cancerous complications have done little to stem the drug's popularity or availability.
"I checked a lot of pharmacies in Kosovo and I noticed that Ozempic is very easy to get," said Kadriu, adding that pharmacists even suggested she gradually increase her dosage.
A worker at a pharmacy in the capital Pristina's downtown, who asked to remain anonymous, said she had trouble recalling when someone last came into her pharmacy to buy Ozempic with a diabetes prescription.
"But we have a constant demand for Ozempic without a prescription. You can guess why," she said.
Given its availability, Emini-Sadiku said authorities should exercise greater control over Ozempic's distribution.
But Bujar Vitija, a journalist specialising in health, said that would be tricky to achieve given Kosovo's poor health record-keeping.
"Unfortunately there is no data," Vitija said.
With 1,500 to 1,600 private pharmacies in Kosovo, the country's 20 pharmaceutical inspectors have their work cut out for them, he added.
- Ozempic 'every day' -
While Kosovo has lower levels of obesity than the European average, more than 57 percent of the population is overweight and 20 percent is clinically obese, according to a 2019 World Health Organization report.
And women, who are more likely to face societal pressure to be thin, were 66 percent more likely to be obese than men, the WHO report found.
But not every Kosovar who has used Ozempic had the best experience with the drug.
"I took Ozempic on the advice of a doctor for two years but it had no effect," said 48-year-old merchant Lulzim Rrahmani, adding that three of his relatives even experienced "a negative effect of the drug".
"It was just a waste of money and time."
Given the risk of side effects, Emini-Sadiku said Ozempic was "by no means to be taken without a doctor's prescription".
Yet Kadriu said she would not be deterred, adding that she saw colleagues taking the drug "every day at work".
"I don't see any symptom that would deter me."
X.Wong--CPN